SMAD3 is an effector protein in TGFβ signaling [105], and the persistent activation of the TGFβ-SMAD3 pathway induces resistance to anti-HER2 drugs and enhances the CSC characteristics of HER2+ BC cells. Here, ERBB2 is linked to breast cancer.